Lazard Capital Downgrades Transcept Pharmaceuticals (TSPT) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts TSPT Hot Sheet
Price: $1.70 --0%
Rating Summary:
1 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
1 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Lazard Capital downgraded Transcept Pharmaceuticals (NASDAQ: TSPT) from Buy to Hold.
For more ratings news on Transcept Pharmaceuticals click here and for the rating history of Transcept Pharmaceuticals click here.
Shares of Transcept Pharmaceuticals closed at $4.87 yesterday.
For more ratings news on Transcept Pharmaceuticals click here and for the rating history of Transcept Pharmaceuticals click here.
Shares of Transcept Pharmaceuticals closed at $4.87 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Barrington Research Downgrades LKQ Corp. (LKQ) to Market Perform
- JPMorgan Downgrades Nick Scali Limited (NCK:AU) to Underweight
Create E-mail Alert Related Categories
DowngradesRelated Entities
LazardSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
